11.1
Farmaceutische equivalenten
Volgens de regelgevende normen vereisen farmaceutische equivalenten dat generieke geneesmiddelen identieke toedieningsvormen hebben en chemisch identi…
Pharmaceutical equivalents deliver the same amounts of active pharmaceutical ingredients or APIs over a similar dosing period.
Generic drugs are pharmaceutically equivalent to the reference drug when they contain the same amount of active pharmaceutical ingredient and have the same dosage form.
They must adhere to compendial standards for potency, content uniformity, disintegration time, and dissolution rate.
Drug content variations are permitted in modified-release dosage forms if the delivered drug amount remains identical to that of the innovator product.
However, different salt forms or prodrugs of the same API are not considered pharmaceutical equivalents under the FDA's definition.
Pharmaceutically equivalent products may contain different excipients or allowable impurities and may also vary in shape, packaging, labeling, and physical attributes.
API characteristics like particle size, polymorphism, purity, stability, and stereochemistry influence pharmaceutical equivalence.
Drug delivery systems, the dosage form’s physical attributes, sterility, overage, and manufacturing processes also affect its equivalence.
View the full transcript and gain access to JoVE Core videos
Q1: What makes a generic drug pharmaceutically equivalent to a brand-name drug?
A generic drug is pharmaceutically equivalent when it contains the same amount of active pharmaceutical ingredient in the same dosage form as the reference drug. It must meet compendial standards for potency, content uniformity, disintegration time, and dissolution rate. These requirements ensure consistent therapeutic performance across batches.
Q2: Can pharmaceutical equivalents differ in their inactive ingredients?
Yes, pharmaceutically equivalent products may contain different excipients and impurities while maintaining the same active ingredient and dosage form. They can also vary in shape, packaging, and labeling. However, these differences must not affect the drug's bioavailability or therapeutic effectiveness.
Q3: How do particle size and polymorphism affect pharmaceutical equivalence?
Particle size, polymorphism, and other API characteristics like purity and stereochemistry directly influence pharmaceutical equivalence. Different polymorphic forms or particle sizes can alter drug dissolution and absorption rates. These factors must remain consistent with the innovator product to maintain equivalence.
Q4: Are different salt forms of the same API considered pharmaceutical equivalents?
No, different salt forms or prodrugs of the same API do not meet the FDA's definition of pharmaceutical equivalents. Although they contain the same active ingredient, variations in salt form or prodrug structure are considered distinct pharmaceutical entities requiring separate regulatory evaluation.
Q5: What role does the manufacturing process play in pharmaceutical equivalence?
Manufacturing processes, drug delivery systems, sterility, and overage significantly affect pharmaceutical equivalence. The physical attributes of the dosage form, including those influenced by formulation and manufacturing process physical attributes, must align with the innovator product to ensure consistent drug delivery and therapeutic outcomes.
Q6: How are modified-release dosage forms evaluated for pharmaceutical equivalence?
Modified-release dosage forms may have variations in drug content as long as the total delivered drug amount remains identical to the innovator product. This flexibility accommodates different release mechanisms while maintaining therapeutic equivalence and ensuring patients receive consistent drug exposure over the dosing period.
Q7: Why is API stability important for maintaining pharmaceutical equivalence?
API stability affects pharmaceutical equivalence because degradation or changes in the active ingredient compromise the drug's potency and therapeutic effectiveness. Stability influences how the drug performs throughout its shelf life, making it essential that generic products maintain stability profiles equivalent to the innovator drug.